Meghan Fitzgerald, Director at Roivant Sciences Ltd. (ROIV), sold 5,112 shares at $39.68 ($203K) on 2026-09-15, disclosed to the SEC on 2026-09-17.
Scheduled sale ($203k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.68 | 4,712 | $187K | 92.0% |
| 2 | $40.45 | 400 | $16K | 8.0% |
| Total | $39.74 avg | 5,112 | $203K | 100% |
| Filing → |
| ROIV | SELL | 2026-03-30 | $1.9M | — | Filing → |
| THC | SELL | 2024-08-08 | $2.9M | — | Filing → |
| THC | SELL | 2021-09-20 | $884K | — | Filing → |